

Paolo Marchetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/81784/publications.pdf>

Version: 2024-02-01

367
papers

11,054
citations

47006

47
h-index

60623

81
g-index

381
all docs

381
docs citations

381
times ranked

15992
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 2 of coronavirus disease (COVID-19) and head and neck cancer: An action plan. <i>Oral Diseases</i> , 2022, 28, 970-972.	3.0	1
2	Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study. <i>Tumori</i> , 2022, 108, 250-257.	1.1	9
3	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. <i>Journal of Hematology and Oncology</i> , 2022, 15, 9.	17.0	5
4	Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1027-1037.	7.0	10
5	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103567.	4.4	26
6	The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature. <i>Frontiers in Oncology</i> , 2022, 12, 797157.	2.8	1
7	Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	3.3	5
8	The Potential Role of Genomic Signature in Stage II Relapsed Colorectal Cancer (CRC) Patients: A Mono-Institutional Study. <i>Cancer Management and Research</i> , 2022, Volume 14, 1353-1369.	1.9	3
9	A 17-Gene Expression Signature for Early Identification of Poor Prognosis in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 178.	3.7	2
10	Patients' Satisfaction with Breakthrough Cancer Pain Therapy: A Secondary Analysis of IOPS-MS Study. <i>Cancer Management and Research</i> , 2022, Volume 14, 1237-1245.	1.9	4
11	Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	3.7	20
12	Immunotherapy and chemo-immunotherapy for non-small cell lung cancer with novel actionable oncogenic driver alterations.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9057-9057.	1.6	0
13	Suppressive immune profile in combined positive score positive head and neck cancer patients treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18014-e18014.	1.6	1
14	Network analysis to determine association between immuno-related toxicities and immune soluble profile in patients treated with anti-PD-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2553-2553.	1.6	0
15	Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3087-3087.	1.6	2
16	Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103176.	4.4	11
17	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021, 142, 18-28.	2.8	81
18	Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study.. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166042.	3.8	61

#	ARTICLE	IF	CITATIONS
19	Drug-Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN [®] System Comprehensive Approach. <i>Pharmaceuticals</i> , 2021, 14, 67.	3.8	9
20	CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. <i>Cancers</i> , 2021, 13, 332.	3.7	35
21	Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098765.	3.2	19
22	Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain. <i>Cancer Management and Research</i> , 2021, Volume 13, 1747-1756.	1.9	2
23	New immunological potential markers for triple negative breast cancer: IL18R1, CD53, TRIM, Jaw1, LTB, PTPRCAP. <i>Discover Oncology</i> , 2021, 12, 6.	2.1	10
24	Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 1080.	3.7	10
25	CT based radiomic approach on first line pembrolizumab in lung cancer. <i>Scientific Reports</i> , 2021, 11, 6633.	3.3	25
26	The role of opioids in cancer response to immunotherapy. <i>Journal of Translational Medicine</i> , 2021, 19, 119.	4.4	24
27	Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC. <i>Cancer Reports</i> , 2021, 4, e1368.	1.4	14
28	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
29	Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice. <i>Frontiers in Oncology</i> , 2021, 11, 657639.	2.8	18
30	Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1525.	2.4	16
31	A Longitudinal Study of Breakthrough Cancer Pain: An Extension of IOPS-MS Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2273.	2.4	2
32	An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case) Tj ETQq0 0 0 rgBT ₂ /Overlock, 10 Tf 50 2	2.2	2
33	A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer. <i>Current Oncology</i> , 2021, 28, 1957-1961.	2.2	3
34	Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. <i>Journal of Personalized Medicine</i> , 2021, 11, 424.	2.5	6
35	Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey. <i>Supportive Care in Cancer</i> , 2021, 29, 7845-7854.	2.2	7
36	Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. <i>Translational Lung Cancer Research</i> , 2021, 10, 2955-2969.	2.8	2

#	ARTICLE	IF	CITATIONS
37	H-Ras gene takes part to the host immune response to COVID-19. <i>Cell Death Discovery</i> , 2021, 7, 158.	4.7	11
38	Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 4737-4745.	7.0	35
39	Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era. <i>Journal of Translational Medicine</i> , 2021, 19, 303.	4.4	1
40	The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. <i>Scientific Reports</i> , 2021, 11, 13770.	3.3	8
41	The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 651.	2.5	28
42	Precision medicine in breast cancer: From clinical trials to clinical practice. <i>Cancer Treatment Reviews</i> , 2021, 98, 102223.	7.7	34
43	Global mapping of cancers: The Cancer Genome Atlas and beyond. <i>Molecular Oncology</i> , 2021, 15, 2823-2840.	4.6	55
44	KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2065-2077.	1.1	28
45	Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?. <i>Cancers</i> , 2021, 13, 4061.	3.7	5
46	Anti-“PD-1 and Anti-“PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 705096.	4.8	47
47	Multidimensional Statistical Technique for Interpreting the Spontaneous Breakthrough Cancer Pain Phenomenon. A Secondary Analysis from the IOPS-MS Study. <i>Cancers</i> , 2021, 13, 4018.	3.7	12
48	The Challenge of ICLs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?. <i>Frontiers in Immunology</i> , 2021, 12, 704942.	4.8	4
49	Vitiligo-like leukoderma—An indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	2.5	2
50	Molecular tests and target therapies in oncology: recommendations from the Italian workshop. <i>Future Oncology</i> , 2021, 17, 3529-3539.	2.4	14
51	Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 695136.	2.8	6
52	Prediction of Recurrence by Machine Learning in Salivary Gland Cancer Patients After Adjuvant (Chemo)Radiotherapy. <i>In Vivo</i> , 2021, 35, 3355-3360.	1.3	3
53	Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patients. <i>Cell Death and Disease</i> , 2021, 12, 1019.	6.3	3
54	Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study. <i>Cancers</i> , 2021, 13, 6355.	3.7	18

#	ARTICLE	IF	CITATIONS
55	Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors. <i>Supportive Care in Cancer</i> , 2020, 28, 1051-1058.	2.2	0
56	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020, 15, 30-37.	1.4	0
57	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929.	5.1	4
58	Preliminary results of a counselling programme for fertility preservation in female cancer patients: The experience of the GEMME DORMIENTI network. <i>European Journal of Cancer Care</i> , 2020, 29, e13174.	1.5	3
59	Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. <i>Lung Cancer</i> , 2020, 140, 59-64.	2.0	33
60	Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. <i>Future Oncology</i> , 2020, 16, 129-145.	2.4	5
61	CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 569-576.	2.8	19
62	Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?. <i>Clinical Endocrinology</i> , 2020, 92, 258-265.	2.4	18
63	Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	2.2	127
64	IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cells. <i>EBioMedicine</i> , 2020, 62, 103098.	6.1	10
65	Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8730.	4.1	75
66	No Evidence of SARS-CoV-2 Circulation in Rome (Italy) during the Pre-Pandemic Period: Results of a Retrospective Surveillance. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8461.	2.6	15
67	Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis. <i>Journal of Translational Medicine</i> , 2020, 18, 446.	4.4	1
68	Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes. , 2020, 8, e000946.		13
69	Gynecological and reproductive factors and the risk of pancreatic cancer: A case-control study. <i>Pancreatology</i> , 2020, 20, 1149-1154.	1.1	3
70	Combination Therapy of High-Dose Rabeprazole Plus Metronomic Capecitabine in Advanced Gastro-Intestinal Cancer: A Randomized Phase II Trial. <i>Cancers</i> , 2020, 12, 3084.	3.7	4
71	Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. <i>Cancers</i> , 2020, 12, 2457.	3.7	3
72	Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 2648.	3.7	10

#	ARTICLE	IF	CITATIONS
73	Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. <i>Translational Lung Cancer Research</i> , 2020, 9, 1533-1542.	2.8	43
74	Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2620.	3.7	21
75	Primary squamous cell carcinoma of major salivary gland: â€œSapienza Head and Neck Unitâ€ clinical recommendations. <i>Rare Tumors</i> , 2020, 12, 203636132097352.	0.6	12
76	Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2âˆ’ Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series. <i>Journal of Personalized Medicine</i> , 2020, 10, 291.	2.5	4
77	Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2. <i>Frontiers in Chemistry</i> , 2020, 8, 590263.	3.6	24
78	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 279.	8.6	32
79	Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients. <i>Journal of Personalized Medicine</i> , 2020, 10, 208.	2.5	23
80	Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study. <i>JCO Precision Oncology</i> , 2020, 4, 1339-1349.	3.0	10
81	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2020, 8, 203.	4.4	38
82	Risk of coronavirus disease 2019 in patients treated for cancer: An immune responseâ€based hypothesis. <i>European Journal of Cancer</i> , 2020, 134, 6-8.	2.8	1
83	Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter â€œSLAVEâ€ Study. <i>Cancers</i> , 2020, 12, 1259.	3.7	19
84	Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3528.	4.1	30
85	The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1513-1527.	2.2	7
86	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of â‰¥50%. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	4.2	60
87	'Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessationâ€™ by Braaten et al: another point of view. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2019-216867.	0.9	6
88	The Exponential Phase of the Covid-19 Pandemic in Central Italy: An Integrated Care Pathway. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3792.	2.6	46
89	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expressionâ‰¥ 50% and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	2.6	50
90	5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1836-1842.	0.9	8

#	ARTICLE	IF	CITATIONS
91	First-line pembrolizumab in advanced non-“small cell lung cancer patients with poor performance status. <i>European Journal of Cancer</i> , 2020, 130, 155-167.	2.8	98
92	Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy. <i>Cancers</i> , 2020, 12, 781.	3.7	8
93	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020, 128, 17-26.	2.8	85
94	Tobacco, Alcohol and Family History of Cancer as Risk Factors of Oral Squamous Cell Carcinoma: Case-Control Retrospective Study. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 3896.	2.5	26
95	The 5-Ws of immunotherapy in head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103041.	4.4	13
96	Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1. <i>Frontiers in Immunology</i> , 2020, 11, 1243.	4.8	30
97	Khorana score and thromboembolic risk in stage II-“III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989985.	3.2	6
98	Adding pertuzumab to adjuvant therapy for high-risk HER2-positive early breast cancer in APHINITY: a GRADE analysis. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 423-430.	1.4	3
99	Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinoma. <i>Endocrine</i> , 2020, 68, 230-232.	2.3	3
100	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. <i>Real-“world evidence. Journal of Cellular Physiology</i> , 2020, 235, 7900-7910.	4.1	19
101	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>Oncolmunology</i> , 2020, 9, 1710389.	4.6	9
102	Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. <i>Journal of Translational Medicine</i> , 2020, 18, 49.	4.4	114
103	Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2020, 9, LMT26.	1.5	9
104	The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. <i>Vaccines</i> , 2020, 8, 191.	4.4	10
105	Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. <i>Outline of the ARIAS Trial. Cancers</i> , 2020, 12, 849.	3.7	2
106	Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 547.	7.1	32
107	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020, 134, 19-28.	2.8	45
108	Circulating Tumor Cells Count Predicts Survival in Colorectal Cancer Patients. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 23, 279-284.	0.9	39

#	ARTICLE	IF	CITATIONS
109	Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis. <i>Oncologist</i> , 2020, 25, e928-e935.	3.7	8
110	New paradigm for stage III melanoma: from surgery to adjuvant treatment. <i>Journal of Translational Medicine</i> , 2019, 17, 266.	4.4	27
111	Clinical Impact of Highly Purified, Whey Proteins in Patients Affected With Colorectal Cancer Undergoing Chemotherapy: Preliminary Results of a Placebo-Controlled Study. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541986692.	2.0	20
112	Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. <i>Anticancer Research</i> , 2019, 39, 4265-4271.	1.1	33
113	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2365-2373.	2.5	9
114	Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center. <i>Journal of Clinical Medicine</i> , 2019, 8, 910.	2.4	28
115	Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer. <i>Clinical Drug Investigation</i> , 2019, 39, 825-834.	2.2	17
116	4th ESPT Conference: pharmacogenomics and personalized medicine“ research progress and clinical implementation. <i>Pharmacogenomics</i> , 2019, 20, 1063-1069.	1.3	1
117	BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. <i>Diagnostics</i> , 2019, 9, 146.	2.6	3
118	Electrochemotherapy as Promising Treatment Option in Rare Recurrent Cutaneous Neoplasm of the Scalp: Case Report of an Elderly Patient. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-5.	0.3	6
119	Response to: Comment on “Impact of tumor site on the prognosis of small bowel adenocarcinoma” Tumori, 2019, 105, 532-532.	1.1	1
120	Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents. <i>European Journal of Pharmacology</i> , 2019, 862, 172621.	3.5	65
121	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. <i>Journal of Translational Medicine</i> , 2019, 17, 296.	4.4	13
122	Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 137, 38-42.	2.0	44
123	A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. <i>Cancers</i> , 2019, 11, 147.	3.7	15
124	Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians’ practice. <i>Supportive Care in Cancer</i> , 2019, 27, 3531-3535.	2.2	3
125	Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 67-72.	4.4	51
126	Unexpected serious aplastic anemia from PD-1 inhibitors: beyond what we know. <i>Tumori</i> , 2019, 105, NP48-NP51.	1.1	8

#	ARTICLE	IF	CITATIONS
127	What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudes. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1439-1444.	0.9	9
128	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. <i>Oncologist</i> , 2019, 24, e327-e337.	3.7	131
129	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
130	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. <i>Clinical Cancer Research</i> , 2019, 25, 3839-3846.	7.0	147
131	The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019, 105, 353-358.	1.1	7
132	A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab. <i>Journal of Translational Medicine</i> , 2019, 17, 99.	4.4	52
133	Study of histopathologic parameters to define the prognosis of stage II colon cancer. <i>International Journal of Colorectal Disease</i> , 2019, 34, 905-913.	2.2	23
134	Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1607.	4.1	40
135	Impact of tumor site on the prognosis of small bowel adenocarcinoma. <i>Tumori</i> , 2019, 105, 524-528.	1.1	12
136	Ion Channel Expression in Human Melanoma Samples: In Silico Identification and Experimental Validation of Molecular Targets. <i>Cancers</i> , 2019, 11, 446.	3.7	21
137	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. <i>Clinical Lung Cancer</i> , 2019, 20, 237-247.e1.	2.6	118
138	Opioid-induced bowel dysfunction: suggestions from a multidisciplinary expert Board. <i>Supportive Care in Cancer</i> , 2019, 27, 4083-4090.	2.2	12
139	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , 2019, 24, 385-393.	3.7	23
140	Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience. <i>Radiation Oncology</i> , 2019, 14, 205.	2.7	16
141	Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. <i>Journal of Cancer</i> , 2019, 10, 5903-5914.	2.5	16
142	Insulin Resistance as a Risk Factor for Cutaneous Melanoma. A Case Control Study and Risk-Assessment Nomograms. <i>Frontiers in Endocrinology</i> , 2019, 10, 757.	3.5	6
143	Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. <i>Journal of Translational Medicine</i> , 2019, 17, 376.	4.4	20
144	Antibodyâ€“Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Nonâ€“small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 989-999.	7.0	315

#	ARTICLE	IF	CITATIONS
145	A multicenter REtrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. <i>Cancer Biology and Therapy</i> , 2019, 20, 192-200.	3.4	30
146	Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPSâ€MS study. <i>European Journal of Pain</i> , 2019, 23, 719-726.	2.8	17
147	Four lines of anaplastic lymphoma kinase inhibitors and brain radiotherapy in a long-surviving non-small-cell lung cancer anaplastic lymphoma kinase-positive patient with leptomeningeal carcinomatosis. <i>Anti-Cancer Drugs</i> , 2019, 30, 201-204.	1.4	2
148	Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 97-107.	4.2	61
149	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptorâ€positive, advanced breast cancer: A realâ€world experience. <i>Journal of Cellular Physiology</i> , 2019, 234, 7708-7717.	4.1	21
150	The Incidence of Alcoholism in Patients with Advanced Cancer Receiving Active Treatment in Two Tertiary Care Centers in Italy. <i>Alcohol and Alcoholism</i> , 2019, 54, 47-50.	1.6	4
151	KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9013-9013.	1.6	42
152	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	10.7	183
153	Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlo</i>	1.0	15
154	Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. <i>Cancer Biology and Therapy</i> , 2018, 19, 328-334.	3.4	12
155	Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report.. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, e17-e20.	3.4	10
156	Characteristics and care pathways of advanced cancer patients in a palliative-supportive care unit and an oncological ward. <i>Supportive Care in Cancer</i> , 2018, 26, 1961-1966.	2.2	6
157	TK Inhibitor Pazopanib Primes DCs by Downregulation of the Î²-Catenin Pathway. <i>Cancer Immunology Research</i> , 2018, 6, 711-722.	3.4	47
158	Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e457-e470.	2.3	18
159	Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report. <i>Drug Safety - Case Reports</i> , 2018, 5, 12.	0.9	15
160	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 521-536.	10.7	486
161	GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 1396-1401.	4.1	17
162	Neoadjuvant chemotherapy in tripleâ€negative breast cancer: A multicentric retrospective observational study in realâ€life setting. <i>Journal of Cellular Physiology</i> , 2018, 233, 2313-2323.	4.1	33

#	ARTICLE	IF	CITATIONS
163	The use of fentanyl in pain management in head and neck cancer patients: a narrative review. <i>British Journal of Pain</i> , 2018, 12, 155-162.	1.5	9
164	FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1478-1485.	1.6	59
165	Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC. <i>Anticancer Research</i> , 2018, 38, 6029-6039.	1.1	18
166	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. <i>Journal of Clinical Medicine</i> , 2018, 7, 542.	2.4	64
167	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. <i>BMC Cancer</i> , 2018, 18, 932.	2.6	6
168	Treatment responses to antiangiogenic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation. <i>Medicine (United States)</i> , 2018, 97, e10904.	1.0	9
169	Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. <i>United European Gastroenterology Journal</i> , 2018, 6, 1039-1048.	3.8	54
170	Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1146-1155.	1.1	77
171	Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors. <i>Pancreas</i> , 2018, 47, 759-771.	1.1	29
172	Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study. <i>Supportive Care in Cancer</i> , 2018, 26, 4021-4029.	2.2	12
173	Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice. <i>Analytical Cellular Pathology</i> , 2018, 2018, 1-12.	1.4	22
174	Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting. <i>Journal of Translational Medicine</i> , 2018, 16, 129.	4.4	16
175	Factors Influencing the Clinical Presentation of Breakthrough Pain in Cancer Patients. <i>Cancers</i> , 2018, 10, 175.	3.7	44
176	Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 552.	4.8	74
177	Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. <i>European Journal of Cancer</i> , 2018, 100, 126-134.	2.8	83
178	CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2018, 97, 59-61.	2.8	22
179	Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study. <i>Oncotarget</i> , 2018, 9, 30268-30278.	1.8	49
180	Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?. <i>Journal of Translational Medicine</i> , 2018, 16, 219.	4.4	96

#	ARTICLE	IF	CITATIONS
181	Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival. <i>Medical Oncology</i> , 2018, 35, 111.	2.5	29
182	Changes of microbiome profile during nivolumab treatment in NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15020-e15020.	1.6	23
183	Effect of nutritional support with highly purified, whey proteins for malnutrition and sarcopenia in patients affected with stage II-III colorectal or breast cancer: A blind, placebo controlled, randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS10129-TPS10129.	1.6	2
184	Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. <i>Oncotarget</i> , 2018, 9, 25714-25722.	1.8	42
185	Interventions to Reduce Neurological Symptoms in Patients with GBM Receiving Radiotherapy: From Theory to Clinical Practice. <i>Anticancer Research</i> , 2018, 38, 2423-2427.	1.1	11
186	Systemic effect of radiotherapy (RT) followed by programmed death 1 (PD-1) inhibitors in non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 177-177.	1.6	0
187	Next-generation expression analysis (NanoString) to develop prognostic and predictive gene signatures for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 700-700.	1.6	0
188	Anatomic site of metastases can influence response to nivolumab in NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15021-e15021.	1.6	0
189	Updated outcomes of previously irradiated non-small-cell lung cancer (NSCLC) patients (pts) receiving programmed death 1 (PD-1) inhibitors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15158-e15158.	1.6	0
190	Intensive first line Flr-C/FOx-C association of triplet chemotherapy plus cetuximab in <i>RAS</i> wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15517-e15517.	1.6	0
191	Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderlyâ€” Preliminary results of the GIM-13 AMBRA study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13078-e13078.	1.6	0
192	The microbiota impact: bacteria shaping immunity, disease and response to therapy. <i>Translational Cancer Research</i> , 2018, 7, S616-S619.	1.0	0
193	Re. â€œAwareness and consideration of malnutrition among oncologists: Insights from an exploratory surveyâ€” <i>Nutrition</i> , 2017, 39-40, 96-97.	2.4	1
194	The factor structure and use of the <scp>Demoralization Scale</scp> (<scp>DSâ€”T</scp>) in Italian cancer patients. <i>Psycho-Oncology</i> , 2017, 26, 1965-1971.	2.3	32
195	Tackling pancreatic cancer with metronomic chemotherapy. <i>Cancer Letters</i> , 2017, 394, 88-95.	7.2	8
196	Current achievements and future perspectives of metronomic chemotherapy. <i>Investigational New Drugs</i> , 2017, 35, 359-374.	2.6	25
197	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017, 82, 237-246.	2.8	38
198	Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients. <i>Pharmacogenomics</i> , 2017, 18, 821-830.	1.3	12

#	ARTICLE	IF	CITATIONS
199	SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab. <i>Medical Oncology</i> , 2017, 34, 75.	2.5	23
200	Knowledge and Attitudes of Young Italian Medical Oncologists Toward the Approach and Treatment of Pain: No Changes, Despite the Law. <i>Pain Medicine</i> , 2017, 18, 1822-1824.	1.9	3
201	5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX. <i>Anti-Cancer Drugs</i> , 2017, 28, 322-326.	1.4	10
202	A nomogram to predict 5-fluorouracil toxicity. <i>Anti-Cancer Drugs</i> , 2017, 28, 551-556.	1.4	10
203	Complete Tumor Response with Afatinib 20mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. <i>Clinical Drug Investigation</i> , 2017, 37, 581-585.	2.2	2
204	Patient database analysis of fulvestrant 500mg in the treatment of metastatic breast cancer: A European perspective. <i>Breast</i> , 2017, 32, 247-255.	2.2	12
205	Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. <i>Scientific Reports</i> , 2017, 7, 10597.	3.3	16
206	Nutritional support for cancer patients: still a neglected right?. <i>Supportive Care in Cancer</i> , 2017, 25, 3001-3004.	2.2	42
207	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. <i>European Journal of Cancer</i> , 2017, 83, 106-115.	2.8	25
208	The role of stereotactic body radiation therapy in oligometastatic colorectal cancer. <i>Medicine (United States)</i> , 2017, 96, e9023.	1.0	14
209	Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate. <i>Anti-Cancer Drugs</i> , 2017, 28, 110-115.	1.4	6
210	Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 157-164.	1.9	12
211	Dignity and Psychosocial-Related Variables in Advanced and Nonadvanced Cancer Patients by Using the Patient Dignity Inventory-Italian Version. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 279-287.	1.2	38
212	Exploring the Prognostic Role of Microsatellite Instability in Patients With Stage II Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2017, 16, e55-e59.	2.3	17
213	Brain Metastases: Surgical Treatment and Overall Survival. <i>World Neurosurgery</i> , 2017, 97, 169-177.	1.3	45
214	A Real-World Multicentre Retrospective Study of Paclitaxel+Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 1571-1578.	4.1	16
215	Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS). <i>Advances in Therapy</i> , 2017, 34, 120-135.	2.9	19
216	Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer. <i>Oncotarget</i> , 2017, 8, 14050-14057.	1.8	6

#	ARTICLE	IF	CITATIONS
217	Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong. <i>Journal of Thoracic Disease</i> , 2017, 9, E985-E989.	1.4	5
218	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. <i>Frontiers in Immunology</i> , 2017, 8, 386.	4.8	27
219	PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?. <i>BioMed Research International</i> , 2017, 2017, 1-7.	1.9	49
220	Position Paper of the Italian Association of Medical Oncology on Early Palliative Care in Oncology Practice (Simultaneous Care). <i>Tumori</i> , 2017, 103, 9-14.	1.1	26
221	Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study. <i>Oncotarget</i> , 2017, 8, 79884-79896.	1.8	239
222	Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. <i>Oncotarget</i> , 2017, 8, 8890-8899.	1.8	48
223	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. <i>Oncotarget</i> , 2017, 8, 56921-56931.	1.8	53
224	PAX3d mRNA over 2.76 copies/ÅµL in the bloodstream predicts cutaneous malignant melanoma relapse. <i>Oncotarget</i> , 2017, 8, 85479-85491.	1.8	3
225	The sexist behaviour of immune checkpoint inhibitors in cancer therapy?. <i>Oncotarget</i> , 2017, 8, 99336-99346.	1.8	76
226	Targeting the <i>PTTG1</i> oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib. <i>Oncotarget</i> , 2017, 8, 113472-113493.	1.8	15
227	Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes. <i>Anticancer Research</i> , 2017, 37, 2633-2639.	1.1	7
228	Prognostic factors associated with survival and recurrence in resectable gastroesophageal adenocarcinoma: retrospective analysis of 497 patients operated at two Italian centers.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15588-e15588.	1.6	0
229	The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1055-1055.	1.6	1
230	Differential clinical outcome of metastatic colorectal cancer (MCRC) patients (pts) treated with first line Flr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15041-e15041.	1.6	1
231	Ethics in Oncology: Principles and Responsibilities Declared in the Italian Ragusa Statement. <i>Tumori</i> , 2016, 102, e25-e27.	1.1	3
232	A rare case of palatin tonsillar metastasis from small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 709-711.	2.8	4
233	Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature. <i>Translational Lung Cancer Research</i> , 2016, 5, 712-719.	2.8	9
234	Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. <i>Journal of Cancer</i> , 2016, 7, 516-522.	2.5	4

#	ARTICLE	IF	CITATIONS
235	Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?. PLoS ONE, 2016, 11, e0163105.	2.5	10
236	Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. Oncotarget, 2016, 7, 20612-20620.	1.8	21
237	A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer. Anti-Cancer Drugs, 2016, 27, 106-111.	1.4	16
238	Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. Future Oncology, 2016, 12, 2071-2075.	2.4	21
239	Evolving treatments for advanced gastric cancer: appraisal of the survival trend. Expert Review of Anticancer Therapy, 2016, 16, 717-729.	2.4	4
240	High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art. Digestive and Liver Disease, 2016, 48, 1503-1505.	0.9	35
241	Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy. Therapeutic Advances in Medical Oncology, 2016, 8, 450-459.	3.2	16
242	Supportive care services in hemato-oncology centers: a national survey. Supportive Care in Cancer, 2016, 24, 4407-4411.	2.2	2
243	Association Between Proton Pump Inhibitors and Metronomic Capecitabine as Salvage Treatment for Patients With Advanced Gastrointestinal Tumors: A Randomized Phase II Trial. Clinical Colorectal Cancer, 2016, 15, 377-380.	2.3	23
244	Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. Journal of Cellular Physiology, 2016, 231, 2541-2547.	4.1	12
245	A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer. Future Oncology, 2016, 12, 2589-2602.	2.4	6
246	Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness. International Journal of Oncology, 2016, 48, 1581-1589.	3.3	34
247	Risk Management of Onco-Hematological Drugs: How and how Fast can we Improve?. Tumori, 2016, 102, S15-S29.	1.1	2
248	Bevacizumab as First-Line Treatment in HER2-Negative Advanced Breast Cancer: Pros and Cons. Tumori, 2016, 102, 472-480.	1.1	12
249	The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer. Anti-Cancer Drugs, 2016, 27, 1044-1049.	1.4	11
250	High prevalence of ALK+/ROS1+ cases in pulmonary adenocarcinoma of adolescents and young adults. Lung Cancer, 2016, 97, 95-98.	2.0	33
251	Being positive despite illness: The contribution of positivity to the quality of life of cancer patients. Psychology and Health, 2016, 31, 524-534.	2.2	32
252	Attitudes Among Patients With Advanced Cancer Toward Euthanasia and Living Wills. Journal of Pain and Symptom Management, 2016, 51, e3-e6.	1.2	7

#	ARTICLE	IF	CITATIONS
253	Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 57-68.	4.4	15
254	Epidemiology and Characteristics of Episodic Breathlessness in Advanced Cancer Patients: An Observational Study. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 17-24.	1.2	33
255	Current challenges in HER2-positive breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 211-221.	4.4	33
256	Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.2	42
257	The Palliative-Supportive Care Unit in a Comprehensive Cancer Center as Crossroad for Patientsâ€™ Oncological Pathway. <i>PLoS ONE</i> , 2016, 11, e0157300.	2.5	36
258	â€œTriple positiveâ€œ early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016, 7, 17932-17944.	1.8	33
259	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 33381-33390.	1.8	11
260	H2020 and Beyond: Skip Discrepancy between Theory and Practice of Personalized Medicine. A Position Paper by the Italian Society of Personalized Medicine. <i>Current Pharmaceutical Biotechnology</i> , 2016, 17, 926-929.	1.6	9
261	CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy. <i>Eurasian Journal of Medicine</i> , 2016, 48, 10-14.	0.6	9
262	Commentary on â€œA Case of Paratesticular Leiomyosarcoma Successfully Treated with Orchiectomy and Chemotherapyâ€œ. <i>Cancer Research and Treatment</i> , 2016, 48, 422-424.	3.0	0
263	Is it possible to teach pain therapy playing basketball?. <i>Annals of Palliative Medicine</i> , 2016, 5, 71-3.	1.2	0
264	Widespread Renal Polycystosis Induced by Crizotinib. <i>Tumori</i> , 2015, 101, e128-e131.	1.1	5
265	Positive impact of elastography in breast cancer diagnosis: an institutional experience. <i>Journal of Ultrasound</i> , 2015, 18, 321-327.	1.3	7
266	Triple positive breast cancer: A distinct subtype?. <i>Cancer Treatment Reviews</i> , 2015, 41, 69-76.	7.7	83
267	Continuous, low-dose capecitabine for patients with recurrent colorectal cancer. <i>Medical Oncology</i> , 2015, 32, 54.	2.5	25
268	Early onset pancreatic cancer: Risk factors, presentation and outcome. <i>Pancreatology</i> , 2015, 15, 151-155.	1.1	60
269	Awareness of cancer, satisfaction with care, emotional distress, and adjustment to illness: an Italian multicenter study. <i>Psycho-Oncology</i> , 2015, 24, 1088-1096.	2.3	38
270	Italian Oncological Pain Survey (IOPS). <i>Clinical Journal of Pain</i> , 2015, 31, 214-221.	1.9	53

#	ARTICLE	IF	CITATIONS
271	Metformin and breast cancer: Basic knowledge in clinical context. <i>Cancer Treatment Reviews</i> , 2015, 41, 441-447.	7.7	13
272	Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1183-1198.	2.4	11
273	Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram. <i>Oncologist</i> , 2015, 20, 1111-1118.	3.7	15
274	Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 139.	4.4	36
275	Effect of MTHFR Polymorphisms on Gastrointestinal Cancer Risk in Italy. <i>World Journal of Oncology</i> , 2015, 6, 394-397.	1.5	10
276	FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?. <i>World Journal of Oncology</i> , 2015, 6, 437-440.	1.5	5
277	Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study. <i>Journal of Cancer</i> , 2014, 5, 320-327.	2.5	53
278	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2014, 9, e105268.	2.5	33
279	Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 599-607.	2.5	39
280	Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 826-831.	3.4	24
281	Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. <i>Cancer Investigation</i> , 2014, 32, 144-149.	1.3	90
282	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 975-983.	2.4	43
283	A Synchronous Pancreatic Metastasis from Renal Clear Cell Carcinoma, with Unusual CT Characteristics, Completely Regressed after Therapy with Sunitinib. <i>Case Reports in Medicine</i> , 2014, 1-6.	0.7	9
284	Cytokines, Fatigue, and Cutaneous Erythema in Early Stage Breast Cancer Patients Receiving Adjuvant Radiation Therapy. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	42
285	Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 27-42.	4.4	68
286	Gastric Metastases From Testicular Cancer: Case Report and Review of Literature. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 22-24.	1.3	10
287	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>Journal of Neuro-Oncology</i> , 2014, 118, 109-116.	2.9	103
288	Multidisciplinary approach to fetal adenocarcinoma of the lung: A case report. <i>Thoracic Cancer</i> , 2014, 5, 97-100.	1.9	2

#	ARTICLE	IF	CITATIONS
289	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 675-683.	4.2	230
290	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 30.	8.6	97
291	High Expression of the Mismatch Repair Protein MSH6 Is Associated With Poor Patient Survival in Melanoma. <i>American Journal of Clinical Pathology</i> , 2014, 142, 121-132.	0.7	22
292	Clinical experience with ipilimumab 3Âmg/kg; real-world efficacy and safety data from an expanded access programme cohort. <i>Journal of Translational Medicine</i> , 2014, 12, 116.	4.4	149
293	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. <i>European Journal of Cancer</i> , 2014, 50, 121-127.	2.8	149
294	Is a Preoperative Assessment of the Early Recurrence of Pancreatic Cancer Possible after Complete Surgical Resection?. <i>Gut and Liver</i> , 2014, 8, 102-108.	2.9	34
295	Treatment and outcome(s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, e15568-e15568.	1.6	0
296	A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15588-e15588.	1.6	0
297	Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know. <i>Anticancer Research</i> , 2014, 34, 5241-50.	1.1	14
298	Resistance to abiraterone in castration-resistant prostate cancer: a review of the literature. <i>Anticancer Research</i> , 2014, 34, 6265-9.	1.1	15
299	Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. <i>Tumori</i> , 2014, 100, e309-13.	1.1	1
300	Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not). <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 489-490.	2.3	16
301	Predictors of mood disorders in cancer patientsâ€™ caregivers. <i>Supportive Care in Cancer</i> , 2013, 21, 643-647.	2.2	23
302	Arterial thrombotic events and acute coronary syndromes with cancer drugs: Are growth factors the missed link?. <i>International Journal of Cardiology</i> , 2013, 167, 2421-2429.	1.7	30
303	Endocrine Side Effects Induced by Immune Checkpoint Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1361-1375.	3.6	358
304	Metronomic chemotherapy for cancer treatment: a decade of clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 13-33.	2.3	81
305	A Systematic Review of Experimental and Clinical Acupuncture in Chemotherapy-Induced Peripheral Neuropathy. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-7.	1.2	59
306	ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. <i>European Journal of Endocrinology</i> , 2013, 169, R153-R164.	3.7	102

#	ARTICLE	IF	CITATIONS
307	Provision of Palliative Care and Pain Management Services for Oncology Patients. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, S-17-S-27.	4.9	5
308	The Pan European Emesis Registry (PEER): a critical appraisal of the Italian experience. Journal of Chemotherapy, 2013, 25, 309-317.	1.5	2
309	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. ClinicoEconomics and Outcomes Research, 2013, 5, 125.	1.9	23
310	Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. OncoTargets and Therapy, 2013, 6, 1761.	2.0	7
311	Differential Denaturation of Serum Proteome Reveals a Significant Amount of Hidden Information in Complex Mixtures of Proteins. PLoS ONE, 2013, 8, e57104.	2.5	16
312	Genomic and epigenomic alterations in prostate cancer. Frontiers in Endocrinology, 2012, 3, 128.	3.5	13
313	Use of interim [¹⁸ F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy. Leukemia and Lymphoma, 2012, 53, 263-269.	1.3	25
314	Premetastatic niche: ready for new therapeutic interventions?. Expert Opinion on Therapeutic Targets, 2012, 16, S119-S129.	3.4	32
315	Palliative Care in Advanced Cancer Patients: Waiting for Godot. Oncologist, 2012, 17, e8-9; author reply e12.	3.7	2
316	Complete Regression of a Non-small Cell Lung Cancer Choroidal Metastasis with Intravitreal Bevacizumab. Journal of Thoracic Oncology, 2012, 7, 468-469.	1.1	10
317	Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome. Current Signal Transduction Therapy, 2012, 7, 265-288.	0.5	4
318	Information Needs of Patients With Melanoma. Clinical Journal of Oncology Nursing, 2012, 16, 625-632.	0.6	19
319	Treatment-related side effects and quality of life in cancer patients. Supportive Care in Cancer, 2012, 20, 2553-2557.	2.2	34
320	Effectiveness of Liver Metastasectomies in Patients With Metastatic Colorectal Cancer Treated With FIr-B/FOx Triplet Chemotherapy Plus Bevacizumab. Clinical Colorectal Cancer, 2012, 11, 119-126.	2.3	29
321	Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. BMC Cancer, 2012, 12, 216.	2.6	6
322	Chemotherapy for the Biliary Tract Cancers: Moving Toward Improved Survival Time. Journal of Gastrointestinal Cancer, 2012, 43, 396-404.	1.3	24
323	Patient perception of disease control and psychological distress. Cancer Management and Research, 2012, 4, 335.	1.9	12
324	Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 253-253.	1.6	3

#	ARTICLE	IF	CITATIONS
325	Predictors of existential and religious well-being among cancer patients. <i>Supportive Care in Cancer</i> , 2011, 19, 1931-1937.	2.2	25
326	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , 2011, 97, 690-2.	1.1	15
327	Intradermal lymphoscintigraphy at rest and after exercise: a new technique for the functional assessment of the lymphatic system in patients with lymphoedema. <i>Nuclear Medicine Communications</i> , 2010, 31, 547-551.	1.1	32
328	Short-term Radiotherapy followed by Adjuvant Chemotherapy in Poor-Prognosis Patients with Glioblastoma. <i>Tumori</i> , 2010, 96, 60-64.	1.1	24
329	"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (Flr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. <i>BMC Cancer</i> , 2010, 10, 567.	2.6	41
330	Adjuvant endocrine therapy for perimenopausal women with early breast cancer. <i>Breast</i> , 2009, 18, 2-7.	2.2	14
331	Overcoming Cultural Barriers to Giving Bad News: Feasibility of Training to Promote Truth-Telling to Cancer Patients. <i>Journal of Cancer Education</i> , 2009, 24, 180-185.	1.3	34
332	A Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of 5-Fluorouracil Degradation Rate by Intact Peripheral Blood Mononuclear Cells. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 482-488.	2.0	31
333	Timed-Flat Infusion of 5-Fluorouracil Associated with Docetaxel as First-Line Treatment of Patients with Metastatic Breast Cancer. <i>Breast Journal</i> , 2008, 14, 116-117.	1.0	0
334	Clinical Classification of <i>BRCA1</i> DNA Missense Variants: H1686Q Is a Novel Pathogenic Mutation Occurring in the Ontogenetically Invariant THV Motif of the N-Terminal BRCT Domain. <i>Journal of Clinical Oncology</i> , 2008, 26, 4212-4214.	1.6	15
335	Inappropriate Doses of Chemotherapy in Italian Breast Cancer Patients Enrolled in Clinical Trials. <i>Tumori</i> , 2007, 93, 540-543.	1.1	1
336	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 289-296.	2.5	27
337	Improving the accuracy of <i>BRCA1/2</i> mutation prediction: validation of the novel country-customized IC software. <i>European Journal of Human Genetics</i> , 2006, 14, 49-54.	2.8	16
338	Novel <i>BRCA1</i> and <i>BRCA2</i> germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 83-91.	2.5	21
339	Gabapentin in the treatment of severe sweating experienced by advanced cancer patients. <i>Supportive Care in Cancer</i> , 2006, 14, 389-391.	2.2	11
340	Changes of Topoisomerase III α Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free Survival. <i>Clinical Cancer Research</i> , 2006, 12, 1501-1506.	7.0	24
341	Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN- γ Results in the Activation of Specific CD8 $^{+}$ T Cells and Monocyte/Dendritic Cell Precursors. <i>Cancer Research</i> , 2006, 66, 4943-4951.	0.9	108
342	Topical Morphine in the Treatment of Painful Ulcers. <i>Journal of Pain and Symptom Management</i> , 2005, 30, 304-305.	1.2	15

#	ARTICLE	IF	CITATIONS
343	Pain evaluation and management: a survey of Italian radiotherapists. <i>Supportive Care in Cancer</i> , 2005, 13, 215-218.	2.2	3
344	The Supportive Care Task Force at the University of L'Aquila: 2-years experience. <i>Supportive Care in Cancer</i> , 2005, 13, 351-355.	2.2	30
345	Assessment and treatment of symptoms among Italian medical oncologists. <i>Supportive Care in Cancer</i> , 2005, 13, 865-869.	2.2	8
346	Natural medicine: a "new frontier" in oncology?. <i>Annals of Oncology</i> , 2005, 16, 339-340.	1.2	3
347	Efficacy of Treatment With Tetracyclines to Prevent Acneiform Eruption Secondary to Cetuximab Therapy. <i>Archives of Dermatology</i> , 2005, 141, 1173-4.	1.4	27
348	Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. <i>European Journal of Human Genetics</i> , 2004, 12, 899-906.	2.8	55
349	Use of strong opioids in advanced cancer pain: a randomized trial. <i>Journal of Pain and Symptom Management</i> , 2004, 27, 409-416.	1.2	160
350	Pruritus in a patient with advanced cancer successfully treated with continuous infusion of granisetron. <i>Supportive Care in Cancer</i> , 2004, 12, 208-209.	2.2	6
351	Dermoscopic patterns of cutaneous melanoma metastases. <i>Melanoma Research</i> , 2004, 14, 367-373.	1.2	51
352	Different Expressivity of BRCA1 and BRCA2: Analysis of 179 Italian Pedigrees with Identified Mutation. <i>Breast Cancer Research and Treatment</i> , 2003, 81, 71-79.	2.5	22
353	Knowledge and attitudes of italian medical oncology residents toward the approach and treatment of pain. <i>Journal of Pain and Symptom Management</i> , 2003, 26, 590-592.	1.2	6
354	New mutations and protein variants of NBS1 are identified in cancer cell lines. <i>Genes Chromosomes and Cancer</i> , 2003, 36, 198-204.	2.8	15
355	High sensitivity of detection of TP53 somatic mutations by fluorescence-assisted mismatch analysis. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 86-91.	2.8	15
356	Weekly administration of paclitaxel: theoretical and clinical basis. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 44, 3-13.	4.4	70
357	Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 1092-1098.	0.8	98
358	Postoperative adjuvant chemoradiation in completely resected locally advanced gastric cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 1069-1075.	0.8	16
359	Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. <i>Human Mutation</i> , 2001, 18, 163-164.	2.5	215
360	Radiotherapy with or without Androgen Deprivation in the Treatment of Localized Adenocarcinoma of the Prostate. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 1-5.	1.3	9

#	ARTICLE	IF	CITATIONS
361	Combined effects of estradiol, leuporelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 1994, 120, 605-609.	2.5	9
362	Natural Interferon- β Treatment and Steroid Hormone Receptors in Primary Endometrial Cancer. <i>Gynecologic Oncology</i> , 1993, 50, 185-190.	1.4	6
363	Steroid receptor enhancement by natural interferon- β in advanced breast cancer. <i>European Journal of Cancer</i> , 1993, 29, 329-333.	2.8	21
364	Glucocorticoid Receptors Predict Response to Combination Chemotherapy in Patients with Acute Lymphoblastic Leukemia. <i>Oncology</i> , 1987, 44, 13-16.	1.9	20
365	Prediction of clinical response to glucocorticoids in children with acute lymphoblastic leukemia. <i>European Paediatric Haematology and Oncology</i> , 1984, 1, 33-36.	0.3	10
366	Presence and steroid inducibility of glutamine synthetase in human leukemic cells. <i>The Journal of Steroid Biochemistry</i> , 1983, 19, 1665-1670.	1.1	6
367	Glucocorticoid receptor studies in human leukemia. <i>The Journal of Steroid Biochemistry</i> , 1981, 15, 261-268.	1.1	16